Replies to post #149215 on Cytodyn Inc (CYDY)

[Leronlimab4DaWin]

They failed CD12, why would I cover?

Prior to COVID this had a $50mm enterprise value on 300mm share outstanding. Now it has a $3B enterprise value on 600mm+ shares outstanding

Price target, since they failed all COVID trials, is back to $50mm EV or $0.08 price per share